<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; IPO</title>
	<atom:link href="http://www.tapanray.in/tag/ipo/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Will ‘Patent Thicket’ Delay Biosimilar Drug Entry in India?</title>
		<link>http://www.tapanray.in/will-patent-thicket-delay-biosimilar-drug-entry-in-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=will-patent-thicket-delay-biosimilar-drug-entry-in-india</link>
		<comments>http://www.tapanray.in/will-patent-thicket-delay-biosimilar-drug-entry-in-india/#comments</comments>
		<pubDate>Mon, 22 Apr 2019 00:00:21 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[3d]]></category>
		<category><![CDATA[ABBvie]]></category>
		<category><![CDATA[AstraZeneca]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[Cyltezo]]></category>
		<category><![CDATA[delay]]></category>
		<category><![CDATA[demand]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[entry]]></category>
		<category><![CDATA[evergreening]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Humira]]></category>
		<category><![CDATA[incremental]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[interest]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[IPO]]></category>
		<category><![CDATA[linkage]]></category>
		<category><![CDATA[lobbyists]]></category>
		<category><![CDATA[Losec]]></category>
		<category><![CDATA[MNC]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[nexium]]></category>
		<category><![CDATA[Office]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[Prilosec]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[section]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Thicket]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9496</guid>
		<description><![CDATA[Do pharma and biotech investors encourage companies indulging in ‘patent thicket?’ This question recently grabbed media headlines. On April 02, 2019, one such report brought out: AbbVie investors are calling for the Chair-CEO power split, flagging the CEO’s USD 4 million bonus payout, fueled &#8230; <a href="http://www.tapanray.in/will-patent-thicket-delay-biosimilar-drug-entry-in-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/will-patent-thicket-delay-biosimilar-drug-entry-in-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>For Drug Safety Concern: “Whistleblower’s Intention Should Be Nationalistic”</title>
		<link>http://www.tapanray.in/for-drug-safety-concern-whistleblowers-intention-should-be-nationalistic/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=for-drug-safety-concern-whistleblowers-intention-should-be-nationalistic</link>
		<comments>http://www.tapanray.in/for-drug-safety-concern-whistleblowers-intention-should-be-nationalistic/#comments</comments>
		<pubDate>Mon, 14 Mar 2016 00:00:09 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2012]]></category>
		<category><![CDATA[2016]]></category>
		<category><![CDATA[Anti-nationalistic]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[CDA]]></category>
		<category><![CDATA[CDSCO]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[Committee]]></category>
		<category><![CDATA[Compulsory]]></category>
		<category><![CDATA[concern]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[Dinesh]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[IPO]]></category>
		<category><![CDATA[License]]></category>
		<category><![CDATA[MCI]]></category>
		<category><![CDATA[Office]]></category>
		<category><![CDATA[Parliament]]></category>
		<category><![CDATA[Parliamentary]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[PIL]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Report]]></category>
		<category><![CDATA[Safety]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Thakur]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[Whistleblower]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7529</guid>
		<description><![CDATA[In the recent weeks, three significant developments related to the Pharmaceutical Industry in India, have triggered rejuvenated concerns in the following critical areas:  A. Overall drug safety standards in the country B.  Self serving interest, rather than patients’ interest, dominate &#8230; <a href="http://www.tapanray.in/for-drug-safety-concern-whistleblowers-intention-should-be-nationalistic/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/for-drug-safety-concern-whistleblowers-intention-should-be-nationalistic/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>The Curious Imbroglio: Innovation, IPR, India and ‘Uncle Sam’</title>
		<link>http://www.tapanray.in/the-curious-imbroglio-innovation-ipr-india-and-uncle-sam/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=the-curious-imbroglio-innovation-ipr-india-and-uncle-sam</link>
		<comments>http://www.tapanray.in/the-curious-imbroglio-innovation-ipr-india-and-uncle-sam/#comments</comments>
		<pubDate>Mon, 04 May 2015 00:00:42 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2005]]></category>
		<category><![CDATA[2015]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[Arvind]]></category>
		<category><![CDATA[Ayog]]></category>
		<category><![CDATA[bullying]]></category>
		<category><![CDATA[curious]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[imbroglio]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[IPO]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[Modi]]></category>
		<category><![CDATA[Niti]]></category>
		<category><![CDATA[OCR]]></category>
		<category><![CDATA[Panagariya]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[Prime Minister]]></category>
		<category><![CDATA[priority watch list]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Special 301]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Think Tank]]></category>
		<category><![CDATA[TRIPS]]></category>
		<category><![CDATA[Uncle Sam]]></category>
		<category><![CDATA[USTR]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6572</guid>
		<description><![CDATA[Last week, the Office of the United States Trade Representative (USTR) released the “2015 Special 301 Report”, which is its annual review of the global state of Intellectual Property Rights (IPR) protection and enforcement. While looking through the Kaleidoscope of &#8230; <a href="http://www.tapanray.in/the-curious-imbroglio-innovation-ipr-india-and-uncle-sam/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/the-curious-imbroglio-innovation-ipr-india-and-uncle-sam/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Awaiting ‘The Moment of Truth’ on ‘Working of Patents’ in India</title>
		<link>http://www.tapanray.in/awaiting-the-moment-of-truth-on-working-of-patents-in-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=awaiting-the-moment-of-truth-on-working-of-patents-in-india</link>
		<comments>http://www.tapanray.in/awaiting-the-moment-of-truth-on-working-of-patents-in-india/#comments</comments>
		<pubDate>Mon, 03 Nov 2014 00:00:53 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[Cipla]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[Compulsory]]></category>
		<category><![CDATA[COPD]]></category>
		<category><![CDATA[DIPP]]></category>
		<category><![CDATA[evergreening]]></category>
		<category><![CDATA[Form 27]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[Glivec]]></category>
		<category><![CDATA[groups]]></category>
		<category><![CDATA[Indacaterol]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[inventive]]></category>
		<category><![CDATA[IPO]]></category>
		<category><![CDATA[Licensing]]></category>
		<category><![CDATA[Lobby]]></category>
		<category><![CDATA[Lupin]]></category>
		<category><![CDATA[moment]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[Onbrez]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Section 66]]></category>
		<category><![CDATA[Section 92]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[truth]]></category>
		<category><![CDATA[Unibrez Rotacaps]]></category>
		<category><![CDATA[working]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6148</guid>
		<description><![CDATA[By a letter dated October 21, 2014 addressed to the Secretary, Department of Industrial Policy and Promotion (DIPP) of India, the domestic pharma major Cipla has sought for the revocation of five patents of Novartis AG’s respiratory drug Indacaterol (Onbrez) in India, &#8230; <a href="http://www.tapanray.in/awaiting-the-moment-of-truth-on-working-of-patents-in-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/awaiting-the-moment-of-truth-on-working-of-patents-in-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>MNCs to Challenge MNC Patents in India: Boon for Patients?</title>
		<link>http://www.tapanray.in/mncs-to-challenge-mnc-patents-in-india-boon-for-patients/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=mncs-to-challenge-mnc-patents-in-india-boon-for-patients</link>
		<comments>http://www.tapanray.in/mncs-to-challenge-mnc-patents-in-india-boon-for-patients/#comments</comments>
		<pubDate>Mon, 16 Sep 2013 00:00:53 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[Africa]]></category>
		<category><![CDATA[BDR]]></category>
		<category><![CDATA[Biocon]]></category>
		<category><![CDATA[boon]]></category>
		<category><![CDATA[Brazil]]></category>
		<category><![CDATA[challenge]]></category>
		<category><![CDATA[Change]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[Compulsory]]></category>
		<category><![CDATA[deep]]></category>
		<category><![CDATA[frivolous]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[Herceptin]]></category>
		<category><![CDATA[highest]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indonesia]]></category>
		<category><![CDATA[IPO]]></category>
		<category><![CDATA[Kabi]]></category>
		<category><![CDATA[Lantus]]></category>
		<category><![CDATA[laws]]></category>
		<category><![CDATA[License]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[MNC]]></category>
		<category><![CDATA[Mylan. Frsenius]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[pocket]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[protests. patients]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[revocation]]></category>
		<category><![CDATA[Saga]]></category>
		<category><![CDATA[Sanofi]]></category>
		<category><![CDATA[South]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Thiland]]></category>
		<category><![CDATA[weak]]></category>
		<category><![CDATA[winds]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=3650</guid>
		<description><![CDATA[Close on the heels of a reasonably successful patent challenge by the German pharma Multinational Corporation (MNC) Fresenius Kabi for the breast cancer drug Tykerb of GlaxoSmithKline (GSK) in India, another MNC Mylan, with its headquarter in the United states, &#8230; <a href="http://www.tapanray.in/mncs-to-challenge-mnc-patents-in-india-boon-for-patients/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/mncs-to-challenge-mnc-patents-in-india-boon-for-patients/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>India, China Revoke Four Pharma Patents in A Fortnight: A Double Whammy for MNCs?</title>
		<link>http://www.tapanray.in/india-china-revoke-four-pharma-patents-in-a-fortnight-a-double-whammy-for-mncs/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=india-china-revoke-four-pharma-patents-in-a-fortnight-a-double-whammy-for-mncs</link>
		<comments>http://www.tapanray.in/india-china-revoke-four-pharma-patents-in-a-fortnight-a-double-whammy-for-mncs/#comments</comments>
		<pubDate>Mon, 12 Aug 2013 00:00:58 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[Allergan]]></category>
		<category><![CDATA[angry]]></category>
		<category><![CDATA[AstraZeneca]]></category>
		<category><![CDATA[benefit]]></category>
		<category><![CDATA[Brazil]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[Cipla]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[Combigan]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[Compulsory]]></category>
		<category><![CDATA[Court]]></category>
		<category><![CDATA[disputes]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[erlotinib]]></category>
		<category><![CDATA[Ganfort]]></category>
		<category><![CDATA[Gefitinib]]></category>
		<category><![CDATA[genuine]]></category>
		<category><![CDATA[Glivec]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[hepatiris B]]></category>
		<category><![CDATA[Hetero]]></category>
		<category><![CDATA[HIV/AIDS]]></category>
		<category><![CDATA[incremental]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovator]]></category>
		<category><![CDATA[invention]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[IPA]]></category>
		<category><![CDATA[IPAB]]></category>
		<category><![CDATA[IPO]]></category>
		<category><![CDATA[Iressa]]></category>
		<category><![CDATA[Law]]></category>
		<category><![CDATA[License]]></category>
		<category><![CDATA[Merck]]></category>
		<category><![CDATA[MNC]]></category>
		<category><![CDATA[Natco]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[patentability]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[pegasys]]></category>
		<category><![CDATA[Pfizer]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[prevails]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[revoked]]></category>
		<category><![CDATA[Roche]]></category>
		<category><![CDATA[Sanofi]]></category>
		<category><![CDATA[SRT]]></category>
		<category><![CDATA[study]]></category>
		<category><![CDATA[Supreme]]></category>
		<category><![CDATA[Sutent]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tarceva]]></category>
		<category><![CDATA[TRIPS]]></category>
		<category><![CDATA[Tykerb]]></category>
		<category><![CDATA[wockhardt]]></category>
		<category><![CDATA[WTO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=3326</guid>
		<description><![CDATA[Revocation of four pharma patents by India and China within a fortnight has raised many eyebrows, yet again, across the globe. In this short period, India has revoked three patents and China one. While this quick development is probably a &#8230; <a href="http://www.tapanray.in/india-china-revoke-four-pharma-patents-in-a-fortnight-a-double-whammy-for-mncs/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/india-china-revoke-four-pharma-patents-in-a-fortnight-a-double-whammy-for-mncs/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Does the Landmark Glivec Judgment Discourage Innovation in India?</title>
		<link>http://www.tapanray.in/does-the-landmark-glivec-judgment-discourage-innovation-in-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=does-the-landmark-glivec-judgment-discourage-innovation-in-india</link>
		<comments>http://www.tapanray.in/does-the-landmark-glivec-judgment-discourage-innovation-in-india/#comments</comments>
		<pubDate>Mon, 08 Apr 2013 00:00:19 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[191]]></category>
		<category><![CDATA[2005]]></category>
		<category><![CDATA[3d]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[AstraZeneca]]></category>
		<category><![CDATA[Case]]></category>
		<category><![CDATA[Challenges]]></category>
		<category><![CDATA[Cipal]]></category>
		<category><![CDATA[commission]]></category>
		<category><![CDATA[Court]]></category>
		<category><![CDATA[Delhi]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[efficacy]]></category>
		<category><![CDATA[gefitinib. Roche]]></category>
		<category><![CDATA[Glenmark]]></category>
		<category><![CDATA[Glivec]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[highcourt]]></category>
		<category><![CDATA[incremental]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[innovative]]></category>
		<category><![CDATA[Innovators]]></category>
		<category><![CDATA[interpretation]]></category>
		<category><![CDATA[IPA]]></category>
		<category><![CDATA[IPO]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[Janumet]]></category>
		<category><![CDATA[Januvia]]></category>
		<category><![CDATA[Judgment]]></category>
		<category><![CDATA[knowledge]]></category>
		<category><![CDATA[landmark]]></category>
		<category><![CDATA[medicines. imatinib]]></category>
		<category><![CDATA[mesylate]]></category>
		<category><![CDATA[MSD]]></category>
		<category><![CDATA[Natco]]></category>
		<category><![CDATA[National]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[organization]]></category>
		<category><![CDATA[out]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[patentability]]></category>
		<category><![CDATA[pegasys]]></category>
		<category><![CDATA[Pfizer]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[revocation]]></category>
		<category><![CDATA[section]]></category>
		<category><![CDATA[Socioeconomic]]></category>
		<category><![CDATA[step]]></category>
		<category><![CDATA[stutent]]></category>
		<category><![CDATA[Supreme]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[therapeutic]]></category>
		<category><![CDATA[time]]></category>
		<category><![CDATA[TRIPS]]></category>
		<category><![CDATA[WHO]]></category>
		<category><![CDATA[with]]></category>
		<category><![CDATA[wockhardt]]></category>
		<category><![CDATA[World]]></category>
		<category><![CDATA[Zita]]></category>
		<category><![CDATA[Zita-Met]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=2150</guid>
		<description><![CDATA[No, I do not think so. The 112 pages well articulated judgment of the Supreme Court of India delivered on April 1, 2013, does not even remotely discourage innovation in India, including much talked about ‘incremental innovation’. This landmark judgment &#8230; <a href="http://www.tapanray.in/does-the-landmark-glivec-judgment-discourage-innovation-in-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/does-the-landmark-glivec-judgment-discourage-innovation-in-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Government Ups the Ante for More Compulsory Licenses in India</title>
		<link>http://www.tapanray.in/government-ups-the-ante-for-more-compulsory-licenses-in-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=government-ups-the-ante-for-more-compulsory-licenses-in-india</link>
		<comments>http://www.tapanray.in/government-ups-the-ante-for-more-compulsory-licenses-in-india/#comments</comments>
		<pubDate>Mon, 21 Jan 2013 00:00:11 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[beds]]></category>
		<category><![CDATA[BMS]]></category>
		<category><![CDATA[BRIC]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[Compulsory]]></category>
		<category><![CDATA[Dasatinib]]></category>
		<category><![CDATA[deficiencies]]></category>
		<category><![CDATA[delivery]]></category>
		<category><![CDATA[distribution]]></category>
		<category><![CDATA[doctors]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Herceptin]]></category>
		<category><![CDATA[hospitals]]></category>
		<category><![CDATA[infrastructure]]></category>
		<category><![CDATA[innovator]]></category>
		<category><![CDATA[IPO]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[Ixabepilone]]></category>
		<category><![CDATA[License]]></category>
		<category><![CDATA[negotiation]]></category>
		<category><![CDATA[NPPP2012]]></category>
		<category><![CDATA[nurses]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[patented]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[predictable]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[process]]></category>
		<category><![CDATA[Roche]]></category>
		<category><![CDATA[skewed]]></category>
		<category><![CDATA[the ante]]></category>
		<category><![CDATA[third]]></category>
		<category><![CDATA[Trastuzumab]]></category>
		<category><![CDATA[treatment]]></category>
		<category><![CDATA[uncertainty]]></category>
		<category><![CDATA[Up]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=1442</guid>
		<description><![CDATA[On January 12, 2013, one of the leading dailies of India first reported that in a move that is intended to benefit thousands of cancer patients, Indian Government has started the process of issuing Compulsory Licenses (CL) for three commonly &#8230; <a href="http://www.tapanray.in/government-ups-the-ante-for-more-compulsory-licenses-in-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/government-ups-the-ante-for-more-compulsory-licenses-in-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Indian Patent office (IPO) asks for details of ‘working of patents’ in India – does it herald the beginning of a new chapter in the IPR regime of the country or it could trigger another raging debate</title>
		<link>http://www.tapanray.in/indian-patent-office-ipo-asks-for-details-of-working-of-patents-in-india-does-it-herald-the-beginning-of-a-new-chapter-in-the-ipr-regime-of-the-country-or-it-could-trigge/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=indian-patent-office-ipo-asks-for-details-of-working-of-patents-in-india-does-it-herald-the-beginning-of-a-new-chapter-in-the-ipr-regime-of-the-country-or-it-could-trigge</link>
		<comments>http://www.tapanray.in/indian-patent-office-ipo-asks-for-details-of-working-of-patents-in-india-does-it-herald-the-beginning-of-a-new-chapter-in-the-ipr-regime-of-the-country-or-it-could-trigge/#comments</comments>
		<pubDate>Mon, 25 Jan 2010 01:30:27 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2005]]></category>
		<category><![CDATA[a]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[another]]></category>
		<category><![CDATA[asks]]></category>
		<category><![CDATA[beginning]]></category>
		<category><![CDATA[chapter]]></category>
		<category><![CDATA[controller]]></category>
		<category><![CDATA[Country]]></category>
		<category><![CDATA[CSPDTM]]></category>
		<category><![CDATA[debate]]></category>
		<category><![CDATA[details]]></category>
		<category><![CDATA[for]]></category>
		<category><![CDATA[herald]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[IPO]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[Office]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Product]]></category>
		<category><![CDATA[raging]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[regime]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[trigger]]></category>
		<category><![CDATA[working]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=479</guid>
		<description><![CDATA[A Public Notice dated 24/12/2009 issued by the Controller General of Patents, Design &#38; Trade Marks, directing all Patentees and Licensees to furnish information in Form No.27 on &#8216;Working of Patents&#8217; as prescribed under Section 146 of the Patents Act &#8230; <a href="http://www.tapanray.in/indian-patent-office-ipo-asks-for-details-of-working-of-patents-in-india-does-it-herald-the-beginning-of-a-new-chapter-in-the-ipr-regime-of-the-country-or-it-could-trigge/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/indian-patent-office-ipo-asks-for-details-of-working-of-patents-in-india-does-it-herald-the-beginning-of-a-new-chapter-in-the-ipr-regime-of-the-country-or-it-could-trigge/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Indian Patent offices (IPOs) have started showing improvement in their functioning; still lot of grounds to cover.</title>
		<link>http://www.tapanray.in/indian-patent-offices-ipos-have-started-showing-improvement-in-their-functioning-still-lot-of-grounds-to-cover/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=indian-patent-offices-ipos-have-started-showing-improvement-in-their-functioning-still-lot-of-grounds-to-cover</link>
		<comments>http://www.tapanray.in/indian-patent-offices-ipos-have-started-showing-improvement-in-their-functioning-still-lot-of-grounds-to-cover/#comments</comments>
		<pubDate>Thu, 10 Dec 2009 01:00:44 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2005]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[CGPDTM]]></category>
		<category><![CDATA[cover]]></category>
		<category><![CDATA[functioning]]></category>
		<category><![CDATA[grounds]]></category>
		<category><![CDATA[Have]]></category>
		<category><![CDATA[improvement]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[IPO]]></category>
		<category><![CDATA[it]]></category>
		<category><![CDATA[lot]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[offices]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Product]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[showing]]></category>
		<category><![CDATA[started]]></category>
		<category><![CDATA[still]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[their]]></category>
		<category><![CDATA[to]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=700</guid>
		<description><![CDATA[Indian Patent offices are located, with four clearly specified jurisdictions, at New Delhi, Mumbai, Kolkata and Chennai. Since last few years enough efforts have been made towards overall capacity building initiatives, training of personnel and digitalizing the huge databank of &#8230; <a href="http://www.tapanray.in/indian-patent-offices-ipos-have-started-showing-improvement-in-their-functioning-still-lot-of-grounds-to-cover/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/indian-patent-offices-ipos-have-started-showing-improvement-in-their-functioning-still-lot-of-grounds-to-cover/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
